Janpix Announces $10 Million Series B Financing to Advance STAT Protein Degrader Pipeline CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders of STAT proteins as novel therapeutics, today...

Potent Preclinical Antitumor Activity Demonstrated by Janpix’s Selective STAT3 & STAT5 Monovalent Degraders to be presented at the Virtual Annual Meetings of the European Hematology Association and American Association for Cancer Research (Part II) CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders as novel therapeutics, today announced the company...

Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors –Addition of Experienced Executive to Leadership Team– CAMBRIDGE, Mass. and MISSISSAUGA, Ontario, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Janpix, Inc., a privately-held biopharmaceutical company...